In clinical trials, anti-CD19 CAR-T expressing a PD-1/CD28 switch receptor was administered to patients with R/R B cell lymphoma, resulting in an overall response rate of 58.8% and a CR rate of 41.2% [152]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.